Watch BCTX. Know when insiders buy.
One email the day a filing lands. Free.
BCTX
BriaCell Therapeutics Corp.
3.58
+0.01 +0.28%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
56
WATCH · shorts 56
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $31.1MP/E —DIV YIELD —FCF YIELD —REV TTM —NET INCOME −$30.7MNET CASH —52W 2.74 – 13.79SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 2026 · Apr 30 | — | — | — | −$7.6M | −$7.2M | — | -0.99 | −$7M | — | — | Jun 9 |
| Q2 2026 · Jan 31 | — | — | — | −$7.5M | −$7.2M | — | -2.58 | −$8M | — | — | Mar 10 |
| Q1 2026 · Oct 31 | — | — | — | −$8.3M | −$8.2M | — | -4.35 | −$7.7M | — | — | Dec 11 |
| Q4 2025 · Jul 31derived | — | — | — | −$8.6M | −$8.1M | — | 4.89 | −$8.1M | — | — | Oct 16 |
| Q3 2025 · Apr 30 | — | — | — | −$6.3M | −$6.1M | −457.1% | -16.42 | −$7.2M | — | — | Jun 9 |
| Q2 2025 · Jan 31 | — | — | — | −$7.2M | −$6.3M | — | -23.31 | −$5.9M | — | — | Mar 10 |
| Q1 2025 · Oct 31 | — | — | — | −$5.2M | −$5.8M | −196.7% | -32.67 | −$7M | — | — | Dec 11 |
| Q4 2024 · Jul 31derived | — | — | — | −$5.8M | −$1.2M | — | -40.32 | −$4M | — | — | Oct 16 |
| Q3 2024 · Apr 30 | — | — | — | −$9.2M | $1.7M | — | 1.61 | −$5.1M | — | — | Jun 16 |
| Q2 2024 · Jan 31 | — | — | — | −$9.8M | −$11.3M | — | -10.64 | −$7.4M | — | — | Mar 12 |
| Q1 2024 · Oct 31 | — | — | — | −$8.5M | $6M | — | -0.50 | −$7.6M | — | — | Dec 16 |
| Q4 2023 · Jul 31derived | — | — | — | −$7.7M | −$2.4M | — | -0.15 | −$10.9M | — | — | Oct 29 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Jul 31 | — | — | −$27.2M | −$26.3M | — | -62.19 | −$28.2M | — | — | — | — |
| FY2024 · to Jul 31 | — | — | −$33.3M | −$4.8M | — | -43.68 | −$24.1M | $457K | −$24.6M | — | — |
| FY2023 · to Jul 31 | — | — | −$23.3M | −$20.3M | — | -1.30 | −$23.7M | — | — | — | — |
| FY2022 · to Jul 31 | — | — | −$15.3M | −$26.8M | — | -1.73 | −$12.5M | — | — | — | — |
| FY2022 · to Jun 30 | — | — | — | — | — | — | — | — | — | — | — |
| FY2021 · to Jul 31 | — | — | −$7M | −$13.8M | — | -3.06 | −$7.8M | — | — | — | — |
Every number comes from BriaCell Therapeutics Corp.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.